{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T09:57:32Z","timestamp":1777802252062,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Child Neurol"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>Subacute sclerosing panencephalitis is a rare progressive inflammatory disease of the central nervous system caused by a persistent aberrant measles virus infection. Cytokines are polypeptides that regulate immune responses and inflammatory reactions. Interleuldn-1\u03b2 has been implicated as a central mediator of tissue damage and destruction in a number of central nervous system diseases. Interleukin-1 receptor antagonist could function as an important anti-inflammatory cytokine. We studied interleukin-1\u03b2 and interleukin-1 receptor antagonist levels in the cerebrospinal fluids of patients with subacute sclerosing panencephalitis and evaluated the effects of different treatment protocols on these cytokines. Interleukin-1\u03b2 and interleukin-1 receptor antagonist levels were measured in 15 patients who had a recent diagnosis of subacute sclerosing panencephalitis (group 1), 6 patients who had been treated with isoprinosine (group 2), 5 patients with intraventricular interferon-\u03b1 (group 3), and 6 patients with interferon-\u03b2 (group 4). The results were compared within the groups and also with the results of 10 patients with other neurologic disease (group 5).The interleukin-1\u03b2 concentrations in cerebrospinal fluid and sera were all below the detection limits (3.9 pg\/mL). Interleukin-1 receptor antagonist levels were not statistically different, except for the group treated with intraventricular interferon-\u03b1. Interleukin-1 receptor antagonist levels were 170 \u00b1 52, 175 \u00b1 58, 1605 \u00b1 518, 77.5 \u00b1 24, and 108 \u00b1 18 pg\/mL in groups 1 to 5, respectively. Interleukin-1 receptor antagonist levels and cerebrospinal fluid serum ratios were significantly increased during interferon-\u03b1 treatment. In conclusion, interleukin-1 and interleukin-1 receptor antagonist levels were not elevated in the patients with subacute sclerosing panencephalitis. The only treatment protocol that affects interleukin-1 receptor antagonist levels in cerebrospinal fluid was intraventricular interferon-\u03b1. Further studies on higher numbers of patients may better document the immunologic status of patients with subacute sclerosing panencephalitis and the effects of different treatment modes. (J Child Neurol 2001;16:417-420).<\/jats:p>","DOI":"10.1177\/088307380101600606","type":"journal-article","created":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T18:40:10Z","timestamp":1206988810000},"page":"417-420","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin-1\u03b2, Interleukin-1 Receptor Antagonist Levels in Patients With Subacute Sclerosing Panencephalitis and the Effects of Different Treatment Protocols"],"prefix":"10.1177","volume":"16","author":[{"given":"Senay","family":"Haspolat","sequence":"first","affiliation":[{"name":"Department of Pediatric Neurology, Akdeniz University Medical School, Antalya, Turkey,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu","family":"Anlar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology Hacettepe University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclsen","family":"K\u00f6se","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Ankara Social Security Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Coskun","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology Akdeniz University Medical School, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olcay","family":"Yegin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology Akdeniz University Medical School, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,6,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1979.00500460044004"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199101000-00013"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92097-9"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.3.488"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0387-7604(93)90120-W"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1177\/088307389801301106"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6614.9"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb03235.x"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1198"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301143280207"},{"key":"atypb11","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.4049\/jimmunol.161.4.1989","volume":"161","author":"Liu Jsh","year":"1998","journal-title":"J Immunol"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1996.0054"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80067-8"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370404"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.4.710"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.3.689"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(92)90033-T"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80171-7"}],"container-title":["Journal of Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/088307380101600606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/088307380101600606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:32:17Z","timestamp":1777494737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/088307380101600606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1177\/088307380101600606"],"URL":"https:\/\/doi.org\/10.1177\/088307380101600606","relation":{},"ISSN":["0883-0738","1708-8283"],"issn-type":[{"value":"0883-0738","type":"print"},{"value":"1708-8283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}